Stevanato Group (NYSE:STVN) Price Target Cut to $20.00 by Analysts at Citigroup

Stevanato Group (NYSE:STVN) had its target price cut by equities researchers at Citigroup from $26.00 to $20.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock.

A number of other equities analysts also recently commented on STVN. Deutsche Bank Aktiengesellschaft began coverage on shares of Stevanato Group in a research note on Wednesday, October 7th. They set a “hold” rating for the company. UBS Group started coverage on shares of Stevanato Group in a report on Wednesday, September 9th. They issued a “neutral” rating and a $23.00 target price on the stock. William Blair cut Stevanato Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Finally, Weiss Ratings upgraded shares of Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

Stevanato Group Stock Down 5.8%

Shares of NYSE STVN traded down €0.81 during midday trading on Wednesday, hitting €13.29. The company’s stock had a trading volume of 4,406,560 shares, compared to its average volume of 533,914. The firm has a market capitalization of $4.02 billion, a price-to-earnings ratio of 23.72, a price-to-earnings-growth ratio of 1.62 and a beta of 0.80. Stevanato Group has a 1 year low of €12.05 and a 1 year high of €27.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08. The business’s fifty day simple moving average is €20.35 and its two-hundred day simple moving average is €18.11.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported €0.16 EPS for the quarter, missing the consensus estimate of €0.17 by (€0.01). The business had revenue of €326.06 million during the quarter. Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%. On average, equities analysts predict that Stevanato Group will post 0.69 EPS for the current year.

Insider Buying and Selling

In other Stevanato Group news, Director Elisabetta Magistretti sold 2,045 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of €20.09, for a total transaction of €41,084.05. Following the sale, the director directly owned 2,930 shares of the company’s stock, valued at €58,863.70. This trade represents a 41.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mauro Stocchi sold 13,649 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of €21.50, for a total transaction of €293,453.50. Following the sale, the insider owned 400,000 shares in the company, valued at approximately €8,600,000. This trade represents a 3.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 21,926 shares of company stock worth $459,738 in the last quarter.

Institutional Trading of Stevanato Group

A number of hedge funds have recently added to or reduced their stakes in STVN. State of Wyoming acquired a new position in Stevanato Group during the third quarter worth approximately $75,000. Schwartz Investment Counsel Inc. raised its stake in Stevanato Group by 15.0% during the third quarter. Schwartz Investment Counsel Inc. now owns 661,136 shares of the company’s stock worth $13,871,000 after purchasing an additional 86,385 shares during the period. PineStone Asset Management Inc. boosted its holdings in shares of Stevanato Group by 8.4% in the 3rd quarter. PineStone Asset Management Inc. now owns 41,335 shares of the company’s stock valued at $867,000 after purchasing an additional 3,200 shares during the last quarter. Fenimore Asset Management Inc acquired a new position in shares of Stevanato Group in the 3rd quarter valued at $12,212,000. Finally, Integrated Wealth Concepts LLC acquired a new position in shares of Stevanato Group in the 2nd quarter valued at $59,000.

Stevanato Group News Summary

Here are the key news stories impacting Stevanato Group this week:

• Positive Sentiment: Third-quarter revenue rose 8% to €326.1 million, providing evidence of continued growth in the business. Stevanato Group Q3 results
• Neutral Sentiment: A Yahoo Finance analysis argues STVN could be 42% undervalued following the earnings report. This is an analyst valuation view, not a company forecast, and contrasts with more cautious broker actions. Valuation analysis
• Negative Sentiment: Management expects only low-single-digit growth in 2027, citing lower GLP-1 syringe volumes associated with one customer. This outlook appears to have overshadowed Q3 revenue growth and contributed to the sharp prior-session selloff. 2027 outlook
• Negative Sentiment: UBS cut its price target to $16 from $23 while retaining a Neutral rating, and William Blair downgraded the stock from Outperform to Market Perform—signs of reduced analyst confidence. UBS target change William Blair downgrade
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations following the November 3 disclosure and share-price decline. These are investigations, not findings of wrongdoing, but may add headline risk. Securities investigation announcement

Stevanato Group Company Profile

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.